Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors

Herwig Strik(Philipps University of Marburg), Mathias Bähr(Medizinische Hochschule Hannover), Ulrich Kaiser(University of Applied Sciences Landshut), Martin Christmann, A. L. Hoffmann, Jan Hendrik Buhk, C. Marosi(University of Vienna), Bernd Kaina(Johannes Gutenberg University Mainz), A. Wrede, Cathryn H. Bock

Journal of Clinical Oncology

May 20, 2008

10.1200/jco.2008.26.15_suppl.13016

Cited by 7

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study

|The Lancet|2001|256

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

|Blood|2021|170